On June 26, 2023 Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eurofins CDMO (part of Eurofins’ network of companies – Eurofins Scientific SE (EURONEXT PARIS: ERF)), a leading global Contract Development and Manufacturing Organization, reported a strategic partnership which will see Eurofins CDMO provide Clinical Trial Supply services to support Ariceum’s current Phase I/II clinical studies in Australia, as well as future clinical studies (Press release, Ariceum Therapeutics, JUN 26, 2023, View Source [SID1234632926]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Initial work on this strategic partnership began one year ago, and the past 12 months have seen the establishment of infrastructure required to support and supply Ariceum’s clinical trials. Services provided to Ariceum Therapeutics by Eurofins CDMO are facilitated in the Eurofins CDMO EUR site in Lentilly, France, which specializes in Clinical Trial Supply services, and comprise, among other services, Qualified Person (QP) release of Drug Substance into Europe, Storage of Drug Substance, Packaging Drug Product, Cold Chain Management (-20oC and 2/8oC) and the management of deliveries of Drug Product to investigational sites. Eurofins CDMO’s short internal process lead times provide Ariceum with the required flexibility to respond to project needs.
Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "Ariceum is pleased to partner with renowned Eurofins CDMO for the supply of its studies. Over the past year Eurofins CDMO has proven to be a flexible and reliable partner. Through this partnership, Ariceum has established the infrastructure required to support and supply the recently initiated Phase I/II trials in Australia as well as future clinical trials."